RenovoRx Inc
RNXT
Company Profile
Business description
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx’s patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy’s toxicities versus systemic intravenous therapy.
Contact
2570 West El Camino Real
Suite 320
Mountain ViewCA94040
USAT: +1 650 284-4433
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
10
Stocks News & Analysis
stocks
Magellan Financial Group: A dilutive acquisition of Barrenjoey
Our view of the proposed merger.
stocks
More US tech stocks look cheap as the market rotates
Meanwhile, value-leaning areas of the market, including industrials and energy stocks, are moving out of undervalued territory.
stocks
Earnings Losers: GYG, DMP & LLC slump on souring market sentiment
The results that fell short of market expectations.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,398.00 | 2.70 | -0.03% |
| CAC 40 | 8,394.32 | 186.43 | -2.17% |
| DAX 40 | 24,638.00 | 646.26 | -2.56% |
| Dow JONES (US) | 48,904.78 | 73.14 | -0.15% |
| FTSE 100 | 10,780.11 | 130.44 | -1.20% |
| HKSE | 26,059.85 | 570.69 | -2.14% |
| NASDAQ | 22,748.86 | 80.64 | 0.36% |
| Nikkei 225 | 58,057.24 | 793.03 | -1.35% |
| NZX 50 Index | 13,628.78 | 27.87 | -0.20% |
| S&P 500 | 6,881.62 | 2.74 | 0.04% |
| S&P/ASX 200 | 9,170.00 | 1.90 | 0.02% |
| SSE Composite Index | 4,182.59 | 19.71 | 0.47% |